<DOC>
	<DOCNO>NCT01239732</DOCNO>
	<brief_summary>This open-label , non-comparative , multi-center study ass safety profile efficacy Avastin ( bevacizumab ) add carboplatin paclitaxel therapy participant epithelial ovarian cancer , fallopian tube carcinoma primary peritoneal carcinoma . Participants receive 15 milligrams/kilogram ( mg/kg ) Avastin intravenously ( IV ) Day 1 every cycle 36 cycle 3 week , carboplatin ( area plasma concentration-time curve [ AUC ] 5-6 mg/ml/min ) Day 1 every 3 week maximum 8 cycle paclitaxel 175 milligram per square meter ( mg/m^2 ) Day 1 every 3 week 80 mg/m^2 every week maximum 8 cycle . The anticipated time study drug 108 week disease progression unacceptable toxicity .</brief_summary>
	<brief_title>A Study Addition Avastin ( Bevacizumab ) Carboplatin Paclitaxel Therapy Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm epithelial ovarian carcinoma , fallopian tube carcinoma , primary peritoneal carcinoma clear cell carcinoma carcinosarcoma . Participants recurrent ovarian cancer previously treat surgery alone early stage disease eligible . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 , 1 2 Life expectancy great equal ( &gt; =3 ) month Participants nonepithelial ovarian cancer , ovarian tumor low malignant potential ( i.e. , borderline tumor ) , synchronous primary endometrial carcinoma Previous systemic therapy ovarian cancer . Prior neoadjuvant chemotherapy allow Planned intraperitoneal cytotoxic chemotherapy Radiotherapy within 28 day Day 1 , Cycle 1 Major surgical procedure , open biopsy significant traumatic injury within 28 day prior first dose Avastin History evidence National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Grade &gt; =1 arterial thromboembolic event Grade &gt; =3 venous thromboembolic event within 6 month prior enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>